Enterprise Value
0.00
Cash
123.6M
Avg Qtr Burn
N/A
Short % of Float
17.90%
Insider Ownership
48.61%
Institutional Own.
56.21%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ORGOVYX (Relugolix) (GnRH receptor antagonist) Details Prostate Cancer | Approved Quarterly sales | |
MYFEMBREE (Relugolix) (GnRH receptor antagonist) Details Reproductive disease, Endometriosis, Uterine disease | Approved Quarterly sales | |
MYFEMBREE (Relugolix) (GnRH receptor antagonist) Details Uterine Fibroids | Approved Quarterly sales |